Results 101 to 110 of about 1,816 (169)

Network pharmacology and molecular docking reveal antiviral mechanisms of silver nanoparticles synthesized by Oscillatoria sp. against HCV pathogenesis. [PDF]

Sci Rep
Azmy L, Al-Olayan E, Abdelhamid MAA, Ibraheem IBM, Zayed A, Gheda SF, Youssif KA, Abou-Zied HA, Abdelmohsen UR, Pack SP, Khalifa HO, Elsayed KNM.   +11 more
europepmc   +1 more source

A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker. [PDF]

Proc Natl Acad Sci U S A
Lahiri H, Israeli E, Krugliak M, Basu K, Britan-Rosich Y, Ravins Yaish T, Arkin IT.   +6 more
europepmc   +1 more source

Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities. [PDF]

Viruses, 2023
Manna S, Das K, Santra S, Nosova EV, Zyryanov GV, Halder S.   +5 more
europepmc   +1 more source

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). [PDF]

Viruses
Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C, Cartabellotta F, Calvaruso V, Di Marco V.   +8 more
europepmc   +1 more source

Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions. [PDF]

Cureus, 2023
Bernal LA, Soti V.
europepmc   +1 more source

Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis. [PDF]

Sci Rep
Mawatari S, Tanoue S, Kumagai K, Oda K, Toyodome A, Sakae H, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Tabu K, Ijuin S, Hori T, Tamai T, Moriuchi A, Kanmura S, Ido A.   +17 more
europepmc   +1 more source

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. [PDF]

Sci Rep
Toyodome A, Mawatari S, Eguchi H, Takeda M, Kumagai K, Taniyama O, Ijuin S, Sakae H, Tabu K, Oda K, Ikeda M, Ido A.   +11 more
europepmc   +1 more source

Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET^® Medical Information Database Network in Japan. [PDF]

Ther Innov Regul Sci, 2022
Hasegawa T, Sawada S, Ishiguro C, Ando T, Kobayashi K, Komiyama N, Iguchi T, Nonaka T, Uyama Y.   +8 more
europepmc   +1 more source

Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study. [PDF]

PLoS One
Park YJ, Yi KY, Woo HY, Heo J, Song GA.
europepmc   +1 more source

Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure. [PDF]

Clin Exp Hepatol, 2023
Tronina O, Brzdęk M, Zarębska-Michaluk D, Lorenc B, Janocha-Litwin J, Berak H, Sitko M, Dybowska D, Mazur W, Tudrujek-Zdunek M, Janczewska E, Klapaczyński J, Dobracki W, Parfieniuk-Kowerda A, Krygier R, Socha Ł, Flisiak R.   +16 more
europepmc   +1 more source